Rns16 Mar 2026 07:04
Christina Coughlin, CEO of Avacta Therapeutics, commented:
"The opening of the first clinical sites in the Phase 1 trial of AVA6103 is an important milestone. It is notable that this program continues to move into clinical development faster than normal industry timelines. With our proprietary sustained release mechanism, we expect AVA6103 to enable greater efficacy from the exatecan payload while limiting the severe toxicities that were observed in the initial development of this payload in the clinic."